COMMUNIQUÉS West-GlobeNewswire

Avivagen Inc. Announces the Granting of Options
22/12/2017
OTTAWA, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSX-V: VIV ) (OTC Pink:CHEXF) (“ Avivagen ” or the “ Company ”), a life sciences innovation company with a series of patent protected products that support and [...]
Saniona AB: Notice of extraordinary shareholders' meeting in Saniona AB
22/12/2017
PRESS RELEASE December 22, 2017 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail . The shareholders in [...]
Serendipity Ixora proposes distribution of its Xbrane shares to its shareholders, after which Serendipity Group becomes the largest shareholder in Xbrane if the distribution is executed
22/12/2017
Press release 2017-12-22 Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") informs that the Company's largest shareholder Serendipity Ixora AB ("Serendipity Ixora"), intends to distribute all its shares in Xbrane [...]
Xbrane Biopharma largest shareholder Serendipity Group issues a credit facility of SEK 50 million to the company
22/12/2017
Press release 2017-12-22 Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has today got issued a credit facility from Serendipity Group AB ("Serendipity Group") of SEK 50 million (the "Credit Facility"). The [...]
Saniona AB: The Nomination Committee of Saniona Proposes Election of Two Additional Members of the Board of Directors
22/12/2017
PRESS RELEASE December 22, 2017 Saniona, a leading biotech company in the field of ion channels, today announced that its Nomination Committee comprised of Søren Skjærbæk appointed by Jørgen Drejer, John Haurum [...]
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
22/12/2017
Priority Review designation based on Phase III study showing 53% reduction in risk of recurrence or death with Tafinlar + Mekinist, as compared to placebo[1] Improvements observed in key secondary endpoints including [...]
Bank of America Merrill Lynch Investment Banking Veteran Joins Hua Medicine as CFO
22/12/2017
SHANGHAI, China, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced George Lin, a seasoned investment banker in the U.S. and Asia, joins Hua [...]
DiaMedica Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
22/12/2017
MINNEAPOLIS, Dec. 21, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V: DMA ) (OTCQB:DMCAF) (the “ Company ”), today announced that at its Annual General and Special Meeting (the “ Meeting ”) of shareholders [...]
La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)
22/12/2017
Giapreza increases blood pressure in adults with septic or other distributive shock La Jolla to host conference call and webcast at 8:30 a.m. EST on December 22, 2017 SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- La [...]
Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit
21/12/2017
COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (“Forward” or the “Company”) today announced the filing of its reply brief to the U.S. Court of Appeals for the Federal Circuit ( [...]
Akers Biosciences Announces Closing of $6,900,000 Public Offering
21/12/2017
THOROFARE, N.J., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or “Akers Bio”), a developer of rapid health information technologies, today announces the closing [...]
Proteostasis Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
21/12/2017
CAMBRIDGE, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI ), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to [...]
Humanigen Signs Definitive Agreements to Exchange Loan Obligations for Equity
21/12/2017
Transactions Create Biotechnology Company Focused on Immunotherapy and Oncology Lenzilumab Begins Development for Treating Key Side-Effects Associated with CAR-T BRISBANE, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) -- [...]
Integra LifeSciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
21/12/2017
PLAINSBORO, N.J., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ), a leading global medical technology company, today announced President and Chief Executive Officer Peter [...]
Ascendis Pharma A/S Announces Participation in 36th Annual J.P. Morgan Healthcare Conference
21/12/2017
COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare [...]
Fluidigm Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM ) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent [...]
ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference
21/12/2017
BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36 th Annual J.P. Morgan Healthcare [...]
GenMark Diagnostics to Present at the J.P. Morgan 36th Annual Healthcare Conference
21/12/2017
CARLSBAD, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK ), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief [...]
Altimmune to Participate in the 10th Annual Biotech Showcase in San Francisco, January 8 – 10, 2018
21/12/2017
GAITHERSBURG, Md., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT ), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a [...]

Pages